Lupin Limited — Important, 30-04-2025: Updates

Lupin Limited is advancing the transfer of its Over-the-Counter Consumer Healthcare Business and API R&D Division to wholly-owned subsidiaries through slump sale transactions. The Business Transfer Agreements for both divisions are expected to be executed by 2025. This strategic shift aims to streamline operations and concentrate on core business areas, potentially improving profitability in the long term.